Sign In
Buy IPSC
$2.07
-0.100 (-4.61%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
08:00am, Thursday, 14'th May 2026
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Century Therapeutics Reports First Quarter Financial Results and Business Updates
08:00am, Wednesday, 13'th May 2026
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived is
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
07:22am, Friday, 24'th Apr 2026
Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.80
02:32am, Thursday, 05'th Mar 2026
Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the firm, Mark
Century Therapeutics to Participate in Upcoming Investor Conferences in March
08:00am, Wednesday, 25'th Feb 2026
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF)
01:13am, Tuesday, 24'th Feb 2026
Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two c
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
11:15am, Monday, 09'th Feb 2026
Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. I
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Thursday, 22'nd Jan 2026
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
09:55am, Wednesday, 07'th Jan 2026
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
09:57am, Tuesday, 09'th Dec 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
04:01pm, Tuesday, 25'th Nov 2025
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
07:30am, Thursday, 13'th Nov 2025
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
